Wall Street brokerages expect that Epizyme, Inc. (NASDAQ:EPZM) will announce ($0.56) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Epizyme’s earnings. The highest EPS estimate is ($0.44) and the lowest is ($0.68). Epizyme posted earnings per share of ($0.51) during the same quarter last year, which would suggest a negative year over year growth rate of 9.8%. The company is expected to announce its next quarterly earnings results on Monday, May 3rd.

On average, analysts expect that Epizyme will report full-year earnings of ($2.21) per share for the current year, with EPS estimates ranging from ($2.69) to ($1.74). For the next financial year, analysts anticipate that the company will report earnings of ($1.65) per share, with EPS estimates ranging from ($2.12) to ($0.38). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Epizyme.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Monday, February 22nd. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.06). The company had revenue of $8.38 billion during the quarter, compared to analysts’ expectations of $6.55 million. Epizyme had a negative return on equity of 83.45% and a negative net margin of 1,899.35%. Epizyme’s revenue for the quarter was up 95.0% compared to the same quarter last year.

A number of equities analysts recently commented on EPZM shares. Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Tuesday, February 9th. SVB Leerink restated a “market perform” rating on shares of Epizyme in a report on Friday, February 5th. Jefferies Financial Group downgraded Epizyme from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $18.00 to $14.00 in a report on Monday, December 21st. Wedbush restated an “outperform” rating on shares of Epizyme in a report on Tuesday, February 23rd. Finally, Morgan Stanley restated an “equal weight” rating and issued a $14.00 price objective on shares of Epizyme in a report on Wednesday, March 3rd. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Epizyme presently has an average rating of “Buy” and a consensus price target of $16.38.

NASDAQ:EPZM traded down $0.01 during mid-day trading on Thursday, reaching $8.43. The stock had a trading volume of 27,204 shares, compared to its average volume of 1,116,394. The business’s 50 day moving average is $9.21 and its 200 day moving average is $11.31. Epizyme has a fifty-two week low of $7.44 and a fifty-two week high of $22.00. The stock has a market cap of $858.05 million, a P/E ratio of -3.75 and a beta of 1.76. The company has a debt-to-equity ratio of 0.33, a current ratio of 8.95 and a quick ratio of 8.71.

In other news, CEO Robert B. Bazemore sold 10,328 shares of the firm’s stock in a transaction on Thursday, March 25th. The shares were sold at an average price of $7.85, for a total value of $81,074.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Matthew Ros sold 2,872 shares of the firm’s stock in a transaction on Monday, January 25th. The stock was sold at an average price of $11.41, for a total transaction of $32,769.52. The disclosure for this sale can be found here. In the last quarter, insiders have sold 27,178 shares of company stock worth $266,862. Corporate insiders own 16.30% of the company’s stock.

Several institutional investors have recently made changes to their positions in EPZM. Norges Bank acquired a new stake in shares of Epizyme in the fourth quarter worth $11,335,000. Morgan Stanley lifted its position in Epizyme by 111.1% in the third quarter. Morgan Stanley now owns 1,449,327 shares of the biopharmaceutical company’s stock worth $17,291,000 after purchasing an additional 762,758 shares during the period. Frazier Management LLC bought a new position in Epizyme in the fourth quarter worth $7,943,000. State Street Corp lifted its position in Epizyme by 16.2% in the third quarter. State Street Corp now owns 4,442,413 shares of the biopharmaceutical company’s stock worth $52,998,000 after purchasing an additional 620,698 shares during the period. Finally, MPM Oncology Impact Management LP lifted its position in Epizyme by 22.4% in the third quarter. MPM Oncology Impact Management LP now owns 2,854,737 shares of the biopharmaceutical company’s stock worth $34,057,000 after purchasing an additional 523,203 shares during the period. Institutional investors and hedge funds own 89.82% of the company’s stock.

Epizyme Company Profile

Epizyme, Inc, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients.

See Also: Special Dividends

Get a free copy of the Zacks research report on Epizyme (EPZM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.